Is Omalizumab Alone an Effective Treatment for Patients with Chronic Spontaneous Urticaria?

Basit Öğe Kaydı
dc.contributor.authorGazioglu, Halil Ibrahim
dc.contributor.authorAyhan, Erhan
dc.date.accessioned2025-02-22T14:08:38Z
dc.date.available2025-02-22T14:08:38Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim While 2(nd )generation antihistamines are the first-line treatment for chronic urticaria (CU), omalizumab is recommended for the treatment of patients with inadequate response to these drugs. This study investigated the need for additional treatment while using omalizumab and the factors affecting this need. Materials and Methods In this study, we retrospectively evaluated the patients who were admitted to our dermatology clinic who started and continued to receive omalizumab at the recommended standard dose between January 01, 2023 and May 01, 2023 for CU. Results Among 90 patients with chronic spontaneous urticaria receiving omalizumab, 51 (56.7%) needed additional treatment, whereas 39 (43.3%) did not need any additional treatment. However, of the 51 patients who developed complaints, 42 (82.4%) had their complaints controlled with antihistamines only, 7 (13.7%) with antihistamines and systemic steroids, 1 (2%) with systemic steroids only, and 1 (2%) with antihistamines, chloroquine, and cyclosporine. Among the patients who used antihistamines to control their complaints, the minimum antihistamine dose was once a day in 33 patients (66%), 2 times a day in 13 patients, 3 times a day in 3 patients and four times in 1 patient. Conclusion A considerable number of patients with CU using omalizumab did not need additional treatment, and the complaints of patients who needed additional treatment were managed with low-dose antihistamines in a short period.en_US
dc.identifier.doi10.4274/tjd.galenos.2024.41636
dc.identifier.endpage129en_US
dc.identifier.issn1307-7635
dc.identifier.issn1308-5255
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85215619194en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage125en_US
dc.identifier.urihttps://doi.org/10.4274/tjd.galenos.2024.41636
dc.identifier.urihttps://hdl.handle.net/11468/29526
dc.identifier.volume18en_US
dc.identifier.wosWOS:001396787300001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofTurk Dermatoloji Dergisi-Turkish Journal of Dermatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectChronic urticariaen_US
dc.subjectomalizumaben_US
dc.subjectantihistamineen_US
dc.titleIs Omalizumab Alone an Effective Treatment for Patients with Chronic Spontaneous Urticaria?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu